Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.
about
Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistanceMechanisms of resistance to anti-EGFR therapy in colorectal cancerVE1 immunohistochemistry predicts BRAF V600E mutation status and clinical outcome in colorectal cancerBRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.Are All Mutations the Same? A Rare Case Report of Coexisting Mutually Exclusive KRAS and BRAF Mutations in a Patient with Metastatic Colon Adenocarcinoma.Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition.
P2860
Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Vemurafenib and panitumumab co ...... orectal cancer: a case report.
@en
type
label
Vemurafenib and panitumumab co ...... orectal cancer: a case report.
@en
prefLabel
Vemurafenib and panitumumab co ...... orectal cancer: a case report.
@en
P2093
P2860
P50
P356
P1476
Vemurafenib and panitumumab co ...... lorectal cancer: a case report
@en
P2093
Alberto Gulino
Amelia Buffone
Antonella Calogero
Carlo Catalano
Emanuela Anastasi
Enrico Cortesi
Matteo Gulino
Paola Frati
P2860
P304
P356
10.4161/CBT.28878
P577
2014-04-22T00:00:00Z